Earnings History Data for Gilead Sciences, Inc. (GILD) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
06-11-2024	AH		GILD	Gilead Sciences, Inc.	111,850	2.02	1.58	2.29	Gilead Sciences Non-GAAP EPS of $2.02 beats by $0.47, revenue of $7.55B beats by $550M [11/6/2024 4:05 PM]	97.84	6.15 (6.71%)	94.36	2.67 (2.91%)	62.07 - 98.32	11,727,303	6,270,000	35,329
Gilead Sciences Non-GAAP EPS of $2.02 beats by $0.47, revenue of $7.55B beats by $550M [11/6/2024 4:05 PM] Gilead rises as it raises 2024 sales, non-GAAP EPS outlook [11/6/2024 5:48 PM] Gilead Sciences in charts: Revenue from major products rises Y/Y in Q3 [11/6/2024 5:58 PM] Gilead Sciences declares $0.77 dividend [11/7/2024 4:16 AM] Top 20 biopharmas market cap rises 2% in Q3 2024 amid flurry of drug approvals [2024-11-06 12:26PM] Analyst Report: Gilead Sciences, Inc. [Nov-05-24 07:19PM] Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World [Nov-05-24 09:15AM]
08-08-2024	AH		GILD	Gilead Sciences, Inc.	92,430	2.01	1.61	1.34	Gilead Sciences Non-GAAP EPS of $2.01 beats by $0.41, revenue of $6.95B beats by $210M [8/8/2024 4:04 PM]	73.69	-1.90 (-2.51%)	75.11	-0.48 (-0.64%)	62.07 - 87.86	6,306,855	6,200,000	32,036
Gilead Sciences Non-GAAP EPS of $2.01 beats by $0.41, revenue of $6.95B beats by $210M [8/8/2024 4:04 PM] Gilead quarterly results beat on both lines and raises full-year non-GAAP EPS outlook [8/8/2024 5:12 PM] Gilead Sciences in charts: Revenue from HIV, liver disease, and oncology therapies advances in Q2 [8/8/2024 4:20 PM]
25-04-2024	AH		GILD	Gilead Sciences, Inc.	83,500	-1.32	-0.23	1.37	Gilead Sciences Non-GAAP EPS of -$1.32 beats by $0.20, revenue of $6.69B beats by $350M [4/25/2024 4:04 PM]	65.42	0.15 (0.23%)	65.93	0.66 (1.01%)	64.63 - 87.86	10,384,131	7,530,000	29,676
Gilead has strong Q1, but updated 2024 EPS guidance range misses consensus [4/25/2024 6:55 PM] Gilead Sciences in charts: Revenue from oncology rises most among products; Veklury dips in Q1 [4/25/2024 4:19 PM] Gilead Sciences Non-GAAP EPS of -$1.32 beats by $0.20, revenue of $6.69B beats by $350M [4/25/2024 4:04 PM] Gilead Sciences declares $0.77 dividend [4/26/2024 10:26 AM]
06-02-2024	AH		GILD	Gilead Sciences, Inc.	95,900	1.72	1.76	1.67	Gilead Sciences Non-GAAP EPS of $1.72 misses by $0.04, revenue of $7.12B beats by $20M [2/6/2024 4:03 PM]	74.48	-3.24 (-4.17%)	76.26	-1.46 (-1.88%)	72.87 - 87.86	9,748,475	7,380,000	17,994
Gilead Sciences Non-GAAP EPS of $1.72 misses by $0.04, revenue of $7.12B beats by $20M [2/6/2024 4:03 PM] Gilead Sciences in charts: HIV revenue drops from last year [2/6/2024 4:28 PM] Gilead Sciences raises dividend by 2.7% to $0.77 [2/6/2024 4:43 PM] Gilead stock dips after hours amid lackluster 2024 sales forecast [2/6/2024 5:51 PM] Gilead drops blood cancer candidate after high mortality risk [2/7/2024 3:17 PM]
07-11-2023	AH		GILD	Gilead Sciences, Inc.	101,660	2.29	1.91	1.90	Gilead Sciences Non-GAAP EPS of $2.29 beats by $0.38, revenue of $7.05B beats by $260M [11/7/2023 4:05 PM]	77.90	-2.71 (-3.36%)	77.47	-3.14 (-3.89%)	72.87 - 89.74	10,765,728	5,820,000	67,821
Gilead Sciences Non-GAAP EPS of $2.29 beats by $0.38, revenue of $7.05B beats by $260M [11/7/2023 4:05 PM] Gilead Sciences in charts: HIV revenue climbs 4% Y/Y; Oncology revenue up 33% [11/7/2023 4:27 PM] Gilead Sciences declares $0.75 dividend [11/8/2023 11:23 AM] Gilead Sciences slips despite Q3 beat and guidance raise [11/8/2023 12:11 PM]
03-08-2023	AH		GILD	Gilead Sciences, Inc.	94,400	1.34	1.60	1.58	Gilead Sciences Non-GAAP EPS of $1.34 misses by $0.30, revenue of $6.59B beats by $140M [8/3/2023 4:03 PM]	78.57	3.04 (4.02%)	77.19	1.66 (2.20%)	60.62 - 89.74	7,707,571	6,810,000	18,772
Gilead Sciences declares $0.75 dividend [8/3/2023 4:06 PM] Gilead Sciences Non-GAAP EPS of $1.34 misses by $0.30, revenue of $6.59B beats by $140M [8/3/2023 4:03 PM] Gilead boosts 2023 sales projection but cuts EPS outlook [8/3/2023 6:27 PM]
27-04-2023	AH	4:00 PM ET (Apr 27)	GILD	Gilead Sciences, Inc.	106,890	1.37	1.63	2.12	Gilead set to continue revenue beat streak with Q1 results [4/26/2023 10:55 AM]	82.12	-1.43 (-1.71%)	83.10	-0.45 (-0.54%)	57.17 - 89.74	8,115,820	5,580,000	24,321
Gilead Sciences beats revenue estimates but misses profit consensus [4/27/2023 4:02 PM] Gilead slips after cutting 2023 earnings guidance [4/27/2023 4:48 PM] Gilead's hepatitis B therapy Vemlidy gets EMA nod for use in kids above 6 [4/28/2023 11:42 AM]
02-02-2023	AH	4:00 PM ET (Feb 2)	GILD	Gilead Sciences, Inc.	104,540	1.67	1.50	0.69		84.50	3.11 (3.81%)	84.40	3.01 (3.70%)	57.17 - 89.74	10,304,914	7,330,000	36,542
Gilead Sciences posts better-than-expected Q4 earnings, 2023 profit mid-point guidance above estimates [2/2/2023 4:01 PM] Gilead Sciences raises dividend by 2.7% to $0.75 [2/2/2023 4:07 PM] Gilead Q4 net income soars 334% YoY helped by massive decline in cost of goods sold [2/2/2023 4:48 PM] Gilead wins FDA nod for Trodelvy in new breast cancer indication [2/3/2023 10:56 AM]
27-10-2022	AH	4:00 PM ET (Oct 27)	GILD	Gilead Sciences, Inc.	87,230	1.90	1.44	2.65	Gilead Sciences Non-GAAP EPS of $1.90 beats by $0.47, revenue of $7.04B beats by $910M, raises FY22 outlook [10/27/2022 4:03 PM]	79.36	9.16 (13.05%)	74.21	4.01 (5.71%)	57.16 - 79.61	24,280,724	7,320,000	303,506
Will Gilead Q3 results bring positive surprise with focus on cancer portfolio? [10/27/2022 10:35 AM] Gilead Sciences Non-GAAP EPS of $1.90 beats by $0.47, revenue of $7.04B beats by $910M, raises FY22 outlook [10/27/2022 4:03 PM] Gilead Sciences raises full-year 2022 outlook following Q3 beats [10/27/2022 5:03 PM] Gilead upgraded to overweight at Piper Sandler on future revenue growth [10/28/2022 9:03 AM] What Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE Can Tell Us [Oct-27-22 09:01AM] Will Gilead Sciences Stock Climb After Q3 Earnings? [Oct-26-22 08:05PM] Drug/Biotech Stocks' Q3 Earnings on Oct 27: MRK, GILD & More [Oct-26-22 02:48PM] Why Gilead (GILD) Could Beat Earnings Estimates Again [Oct-26-22 12:10PM] Gilead Sciences: Metastatic Breast Cancer Advocate Urges Black People to Join Clinical Trials [Oct-26-22 09:00AM]
02-08-2022	AH	4:00 PM ET (Aug 2)	GILD	Gilead Sciences, Inc.	76,260	1.58	1.51	1.87	Gilead Sciences Non-GAAP EPS of $1.58 beats by $0.06, revenue of $6.26B beats by $390M, raises FY22 EPS guidance [8/2/2022 4:04 PM]	62.24	2.70 (4.53%)	60.80	1.26 (2.12%)	57.16 - 74.12	8,020,575	6,410,000	34,996
Gilead Sciences Non-GAAP EPS of $1.58 beats by $0.06, revenue of $6.26B beats by $390M, raises FY22 EPS guidance [8/2/2022 4:04 PM] Gilead raises 2022 guidance following growth in HIV, oncology franchises [8/2/2022 5:14 PM] Gilead Sciences Announces Second Quarter 2022 Financial Results [Aug-02-22 04:01PM] Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More [Aug-01-22 01:59PM] Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season? [Aug-01-22 09:47AM]
28-04-2022	AH	4:00 PM ET (Apr 28)	GILD	Gilead Sciences, Inc.	77,570	2.12	1.77	2.08	Gilead Sciences Non-GAAP EPS of $2.12 beats by $0.31, revenue of $6.59B beats by $310M [4/28/2022 4:04 PM]	59.32	-2.24 (-3.64%)	61.61	0.05 (0.08%)	57.19 - 74.12	7,390,952	7,690,000	3,133
Gilead Sciences Non-GAAP EPS of $2.12 beats by $0.31, revenue of $6.59B beats by $310M [4/28/2022 4:04 PM] Gilead nails Q1 beat even as net income plummets on R&D impairment charge [4/28/2022 5:18 PM] Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More [Apr-27-22 02:03PM] Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News [Apr-27-22 12:44PM] CDC study highlights speed with which omicron variant infected Americans, and WHO warns testing is still crucial [Apr-27-22 10:26AM] Should You Buy Gilead (GILD) Ahead of Earnings? [Apr-27-22 08:38AM] Gilead Sciences Announces First Quarter 2022 Financial Results [Apr-28-22 04:02PM] Gilead Sciences Crushes First-Quarter Views As Covid Drug Adds $1.5 Billion [Apr-28-22 04:35PM] UPDATE 2-Gilead earnings beat Street estimates, writedown taken on cancer drug [Apr-28-22 04:43PM] Gilead earnings beat Street estimates, writedown taken on cancer drug [Apr-28-22 04:25PM] Gilead Sciences (GILD) Beats Q1 Earnings and Revenue Estimates [Apr-28-22 05:25PM] Gilead Sciences (GILD) Q1 2022 Earnings Call Transcript [Apr-29-22 02:00AM] On Earth Day, Gilead Marks Strides in Environmental Sustainability [Apr-29-22 09:26AM] Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales [Apr-29-22 11:05AM] 11 Companies Making Headlines Following Earnings Reports [Apr-29-22 03:45PM] Why These Analysts Are Bullish On Gilead's Q1 Earnings [Apr-29-22 01:57PM]
01-02-2022	AH	4:00 PM ET (Feb 1)	GILD	Gilead Sciences, Inc.	84,380	0.69	1.50	2.19	Gilead Sciences Non-GAAP EPS of $1.87 beats by $0.26, revenue of $7.24B beats by $600M [2/1/2022 4:05 PM]	65.79	-2.68 (-3.91%)	65.70	-2.77 (-4.05%)	61.39 - 74.12	16,213,828	10,570,000	367,082
Gilead’s COVID-19 therapy beats AbbVie’s Humira to lead U.S. hospital spending in 2021 [2/1/2022 3:46 PM] Gilead Sciences Non-GAAP EPS of $1.87 beats by $0.26, revenue of $7.24B beats by $600M [2/1/2022 4:05 PM] Gilead Sciences raises dividend by 3% to $0.73 [2/1/2022 4:14 PM] Gilead shares fall after hours despite top and bottom line quarterly beats [2/1/2022 4:55 PM] Gilead settles patent dispute with ViiV Healthcare over HIV drug [2/1/2022 5:03 PM] Robeco Institutional Asset Management B.V. ... [Jan-31-22 05:38PM] Dfpg Investments, Llc Buys Occidental Petroleum Corp, ESS U.S. ... [Jan-31-22 05:38PM] How to Invest in Biotech When Deep Value Has no Discernible Meaning [Jan-31-22 10:00AM] ARGA Investment Management, LP Buys Petroleo Brasileiro SA Petrobras, Trip. ... [Jan-31-22 09:38AM] U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome [Jan-31-22 09:00AM] Is Gilead Sciences Stock a Buy Now? [Jan-31-22 07:05AM] Inside the Innovation: Pharmaceutical Development and Manufacturing Leaders Share Experiences [Feb-01-22 09:15AM] Should Value Investors Pick Gilead Sciences (GILD) Stock? [Feb-01-22 09:35AM] Gilead COVID drug takes top spot for U.S. hospital spending -report [Feb-01-22 01:42PM] Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results [Feb-01-22 04:02PM] Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend [Feb-01-22 04:10PM] Gilead Stock Dives After Two Major Charges Dig Into Fourth-Quarter Earnings [Feb-01-22 04:18PM] Gilead earnings hurt by legal settlement, other charges [Feb-01-22 04:31PM] Gilead Sciences (GILD) Q4 Earnings Miss Estimates [Feb-01-22 05:35PM] GSK to get $1.25 billion to settle HIV drug patent row with Gilead [Feb-01-22 04:49PM] 10 Stocks to Invest in Today According to Billionaire Kerr Neilson [Feb-02-22 10:32AM] Gilead (GILD) Q4 Earnings Miss on Legal Settlement Charges [Feb-02-22 09:17AM] Amid omicron surge, lagging vax rate, Gilead sees full-year Covid drug sales rise [Feb-02-22 11:04AM] Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More [Feb-02-22 11:27AM] Did Hedge Funds Get Gilead Sciences, Inc. (GILD) Right? [Feb-02-22 03:25PM] Girard Partners Ltd. Buys Vanguard Total International Stock, The Toronto-Dominion Bank, SPDR ... [Feb-02-22 05:38PM] 10 Stocks Drawing Attention on Earnings Reports [Feb-02-22 04:18PM]
28-10-2021	AH	4:00 PM ET (Oct 28)	GILD	Gilead Sciences, Inc.	84,920	2.65	1.72	2.11	Gilead Sciences EPS beats by $0.87, beats on revenue, boost FY21 outlook [10/28/2021 4:04 PM]	64.84	-2.50 (-3.72%)	65.90	-1.44 (-2.14%)	56.56 - 73.34	11,897,178	5,400,000	85,078
Gilead Sciences EPS beats by $0.87, beats on revenue, boost FY21 outlook [10/28/2021 4:04 PM] Gilead and Merck ink collaboration agreement for Keytruda/Trodelvy breast cancer study [10/28/2021 4:19 PM] Gilead lifts 2021 guidance as remdesivir sales more than double in Q3 [10/28/2021 4:28 PM] Gilead's Biktarvy maintains virus suppression in patients with HIV after one year [10/29/2021 8:43 AM] Gilead price target lowered at Cantor as key milestones for cancer drugs delayed [10/29/2021 12:43 PM] Healthcare ETFs in Focus as Q3 Earnings Unfold [Oct-27-21 11:10AM] Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More [Oct-27-21 11:10AM] 2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays [Oct-27-21 10:00AM] Why Gilead (GILD) Might Surprise This Earnings Season [Oct-27-21 08:34AM] Ability to vaccinate 5 year olds & up to be critical in aiding pandemic resolution: Doctor [Oct-28-21 02:21PM] Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer [Oct-28-21 04:10PM] Gilead Sciences Announces Third Quarter 2021 Financial Results [Oct-28-21 04:02PM] Gilead beats profit expectations on COVID-19 drug sales [Oct-28-21 04:22PM] Gilead Crushes Quarterly Forecasts and Raises Outlook For 2021; But Shares Dip [Oct-28-21 04:22PM] Gilead Sciences stock dips as results, outlook top Street view [Oct-28-21 04:39PM] Gilead cuts 2021 sales forecast for non-COVID products [Oct-28-21 04:22PM] UPDATE 1-Gilead cuts 2021 sales forecast for non-COVID products [Oct-28-21 04:51PM] How Gilead's Covid Drug Carried Its Third-Quarter Beat And Why Shares Fell [Oct-28-21 05:33PM] UPDATE 2-Gilead trims 2021 sales forecast for non-COVID products [Oct-28-21 04:51PM] Gilead trims 2021 sales forecast for non-COVID products [Oct-28-21 04:22PM] Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates [Oct-28-21 05:25PM] Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting [Oct-29-21 07:30AM] Gilead Sciences earnings and outlook top Street views [Oct-29-21 08:24AM] Gilead (GILD) Q3 Earnings Beat on Increased Veklury Sales [Oct-29-21 08:09AM] Gilead Falls as Sales of Non-Covid Drugs Seen Weaker [Oct-29-21 06:16AM] Gilead Sciences (GILD) Q3 2021 Earnings Call Transcript [Oct-29-21 11:31AM] People being against getting the Covid-19 vaccine makes no sense to me: Doctor [Oct-29-21 02:33PM] Coronavirus: Americans protesting against vaccines makes no sense to me,' doctor says [Oct-29-21 02:33PM]
29-07-2021	AH	4:00 PM ET (Jul 29)	GILD	Gilead Sciences, Inc.	86,450	1.87	1.76	1.11	Gilead Sciences EPS beats by $0.12, beats on revenue [7/29/2021 4:04 PM]	68.27	-1.56 (-2.23%)	68.69	-1.14 (-1.63%)	56.56 - 72.60	7,563,844	5,840,000	22,411
Gilead Sciences EPS beats by $0.12, beats on revenue [7/29/2021 4:04 PM] Gilead Sciences tightens 2021 guidance; remdesivir sales slide [7/29/2021 4:38 PM] Gilead no longer pursues inhaled version of COVID-19 drug remdesivir [7/30/2021 9:24 AM] Pfizer authorizes $1 billion for oral COVID-19 treatment, CEO says [Jul-28-21 03:45PM] Covid-19 vaccine booster shots will become a reality: Doctor [Jul-28-21 01:51PM] We must move towards vaccine mandates to get ahead of Covid-19: Doctor [Jul-29-21 02:06PM] Gilead Earnings Top Views; Biotech Giant Narrows Guidance [Jul-29-21 04:14PM] Gilead Sciences Announces Second Quarter 2021 Financial Results [Jul-29-21 04:01PM] UPDATE 1-COVID-19 drug sales help boost Gilead 2nd-quarter results, HIV sales dip [Jul-29-21 05:05PM] COVID-19 drug sales help boost Gilead 2nd-quarter results, HIV sales dip [Jul-29-21 04:30PM] UPDATE 2-Gilead's COVID-19 drug helps boost 2nd-quarter results as HIV sales dip [Jul-29-21 05:05PM] Gilead's COVID-19 drug helps boost 2nd-quarter results as HIV sales dip [Jul-29-21 04:30PM] Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates [Jul-29-21 05:25PM] Amazon, Pinterest Fall Premarket; Chevron, P&G Rise [Jul-30-21 04:01AM] Gilead Sciences (GILD) Q2 2021 Earnings Call Transcript [Jul-30-21 09:32AM] Doctor on Delta variant: All of us are extremely concerned [Jul-30-21 01:56PM] Gilead (GILD) Q2 Earnings Beat Estimates, HIV Sales Decline [Jul-30-21 01:12PM]
29-04-2021	AH	4:00 PM ET (Apr 29)	GILD	Gilead Sciences, Inc.	82,800	2.08	2.06	1.68	Gilead Sciences EPS misses by $0.04, misses on revenue [4/29/2021 4:04 PM]	63.36	-0.48 (-0.75%)	62.40	-1.44 (-2.26%)	56.56 - 85.67	10,215,989	6,870,000	55,426
Gilead Sciences EPS misses by $0.04, misses on revenue [4/29/2021 4:04 PM] Gilead down after hours following earnings miss, uncertainty over COVID recovery [4/29/2021 4:34 PM] Gilead Sciences declares $0.71 dividend [4/29/2021 4:41 PM] Its good to lift COVID-19 restrictions right now: UAB Epidemiologist [Apr-28-21 01:32PM] Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News [Apr-28-21 12:18PM] Healthcare ETFs on Radar As Q1 Earnings Unfold [Apr-28-21 12:10PM] Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More [Apr-28-21 11:14AM] Corporate Giants Join the Global Race to Fight India Covid Crisis [Apr-28-21 10:19PM] NYC reopening timeline is a disastrous issue: Doctor [Apr-29-21 01:51PM] Gilead Sciences, Inc. to Host Earnings Call [Apr-29-21 02:30PM] Gilead Sciences Announces Second Quarter 2021 Dividend [Apr-29-21 04:02PM] Gilead Sciences Announces First Quarter 2021 Financial Results [Apr-29-21 04:01PM] Gilead first-quarter profit rises despite lower HIV drug sales [Apr-29-21 04:35PM] Gilead 1st-quarter profit rises despite lower HIV drug sales [Apr-29-21 04:27PM] Gilead stock falls as COVID-19 drug sales dwindle [Apr-29-21 04:27PM] Gilead Stock Dives On Wide First-Quarter Sales Miss, Earnings Meet [Apr-29-21 04:23PM] Gilead HIV, hepatitis C sales dip, shares down 2.3% [Apr-29-21 04:36PM] UPDATE 1-Gilead HIV, hepatitis C sales dip, shares down 2.3% [Apr-29-21 05:02PM] Gilead Stock Dives As Light HIV Drug Sales Lead To Quarterly Miss [Apr-29-21 05:14PM] UPDATE 2-Gilead HIV, hepatitis C sales dip, shares down 2.6% [Apr-29-21 05:02PM] Gilead HIV, hepatitis C sales dip, shares down 2.6% [Apr-29-21 04:36PM] Gilead Sciences (GILD) Q1 Earnings Beat Estimates [Apr-29-21 05:25PM] Gilead Sciences (GILD) Q1 2021 Earnings Call Transcript [Apr-30-21 12:01AM] Gilead's Q1 Results Show Just How Much the Biotech Is Relying on Its COVID Drug [Apr-30-21 06:01AM] Gilead (GILD) Beats on Q1 Earnings, HIV Sales Decline [Apr-30-21 10:00AM] California has lowest COVID-19 case rate in the U.S.: RPT [Apr-30-21 01:37PM]
04-02-2021	AH	4:00 PM ET (Feb 4)	GILD	Gilead Sciences, Inc.	81,640	2.19	2.11	1.10	Gilead Sciences EPS beats by $0.04, beats on revenue [2/4/2021 4:02 PM]	68.38	2.55 (3.87%)	67.28	1.45 (2.20%)	56.56 - 85.97	13,068,102	7,804,377	100,656
Gilead Sciences EPS beats by $0.04, beats on revenue [2/4/2021 4:02 PM] Gilead Sciences hikes dividend by 4.4% to $0.71 per share [2/4/2021 4:31 PM] Why Gilead Sciences Stock Jumped Today [Feb-05-21 03:29PM] Dow Jones Today, Stocks Climb Amid Senate Stimulus Vote, Spotty Payrolls Data; J&J Seeks FDA Vaccine Nod [Feb-05-21 10:00AM] The Zacks Analyst Blog Highlights: Ford, Pinterest, Peloton Interactive, Gilead Sciences and T-Mobile US [Feb-05-21 07:15AM] Gilead Stock Pops After Covid Drug Brings In $2.8 Billion In 2020 Sales [Feb-04-21 04:25PM] Recap: Gilead Sciences Q4 Earnings [Feb-04-21 04:13PM] Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend [Feb-04-21 04:02PM] Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results [Feb-04-21 04:01PM]
28-10-2020	AH	4:00 PM ET (Oct 28)	GILD	Gilead Sciences, Inc.	75,170	2.11	1.83	1.65	Gilead Sciences EPS beats by $0.22, beats on revenue [10/28/2020 4:03 PM]	58.53	-0.19 (-0.32%)	57.98	-0.74 (-1.26%)	57.04 - 85.97	12,013,722	12,641,741	158,380

30-07-2020	AH	4:00 PM ET (Jul 30)	GILD	Gilead Sciences, Inc.	92,480	1.11	1.51	1.72	Gilead Sciences EPS misses by $0.34, misses on revenue [7/30/2020 4:03 PM]	68.71	-3.62 (-5.01%)	69.76	-2.57 (-3.55%)	60.89 - 85.97	9,829,391	6,908,440	163,847